Eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss Syndrome, is a rare autoimmune disorder characterized by necrotizing vasculitis of small-to medium-sized blood vessels and eosinophilic infiltration into tissues and organs. Symptoms of EGPA can vary among patients and may include shortness of breath, sinus problems such as nasal polyps, rashes, neuropathy, and fatigue. It can be challenging to diagnose EGPA due to its diverse clinical presentation.
Although the exact incidence and prevalence of EGPA are not known, an estimated 118,000 individuals worldwide have the condition. Patients with EGPA may experience a significant disease burden due to involvement of multiple organ systems, frequent relapses, and adverse events from standard treatments. While oral corticosteroids and immunosuppressants have traditionally been used to manage EGPA, the disease often remains poorly controlled or relapses, and these medications can have unwanted side effects. This underscores the need for effective treatment options that can address disease activity and inflammation to achieve remission and reduce relapses.
FASENRA® (benralizumab) is a targeted treatment option approved for adults with EGPA. The recommended dosage of FASENRA for EGPA is 30 mg administered subcutaneously once every 4 weeks. The US FDA approval of FASENRA was based on positive results from the MANDARA Phase III trial, which compared the efficacy and safety of FASENRA to mepolizumab in adult patients with relapsing or refractory EGPA.
In the MANDARA trial, FASENRA demonstrated noninferiority to mepolizumab in achieving remission and reducing corticosteroid dosage in patients with EGPA. FASENRA works by depleting eosinophils, which play a role in the inflammation seen in EGPA. The most common adverse reactions to FASENRA include headache and pharyngitis.
FASENRA provides a much-needed treatment option for adults with EGPA and has the potential to address unmet needs in managing this challenging condition. With its unique mechanism of action in depleting eosinophils and reducing inflammation, FASENRA offers a once-monthly treatment option that may benefit patients with EGPA. Guía de 2021 de la American College of Rheumatology/Vasculitis Foundation para el manejo de la vasculitis asociada a anticuerpos anticitoplasma de neutrófilos. Arthritis Rheumatol. 2021;73(8):1366-1383. doi:10.1002/art.41773.
Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. Recomendaciones de la EULAR para el manejo de la vasculitis asociada a ANCA: actualización de 2022. Ann Rheum Dis. 2024;83(1):30-47. doi:10.1136/ard-2022-223764.
Emmi G, Bettiol A, Gelain E, et al. Guía basada en evidencias para el diagnóstico y manejo de la granulomatosis eosinofílica con poliangitis. Nat Rev Rheumatol. 2023;19(6):378-393. doi:10.1038/s41584-023-00958-w.
FASENRA® (benralizumab) [información de prescripción]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; septiembre de 2024.
Wechsler ME, Nair P, Terrier B, et al; Grupo de Estudio MANDARA. Benralizumab versus mepolizumab para la granulomatosis eosinofílica con poliangitis. N Engl J Med. 2024;390(10):911-921.
US-94552 Última actualización 3/25